Key statistics dashboard for MapLight Therapeutics, Inc. (MPLT). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis.
Stock Data
| Price | $11.40 |
| Market Cap | $484M |
| Beta | -2.79 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -2.20 |
| Price / Book | 1.49 |
| P/S | 0.00 |
| P/FCF | -2.76 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 16.52 |
| Quick Ratio | 16.52 |
| Cash Ratio | 3.71 |
| Debt / Equity | 0.01 |
| Debt / Assets | 0.54% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 20.51 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 7.67 |
| Cash per share | 6.71 |
| FCF per share | -3.85 |
| Tangible Book Value per share | 7.67 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 6 |
| Avg rating (1-5) | 1.00 |
Related companies: BRTX · DWTX · EDSA · ERNA · IMRN · LPCN · OSRH
Explore sector: Healthcare · Biotechnology
More sections of MPLT: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks